Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Source: NCBI BioProject (ID PRJNA175066)
Source: NCBI BioProject (ID PRJNA175066)
0 0
Project name: Homo sapiens
Description: 17 patients with myelofibrosis contributed paired research samples; the time points were pre-study and 12 weeks after commencing study treatment with CYT387.Gene expression analysis was investigated to study the effects of drug treatment. Additional analysis invesitigated differences in expression patterns in groups of anemia responders and non-responders following drug treatment.Overall design: 34 samples representing 17 patients. Each patient submitted 1 pre-treatment sample and 1 post 12 weeks of treatment.
Data type: Transcriptome or Gene expression
Sample scope: Multiisolate
Relevance: Medical
Organization: Dr. Pardanani, Hematology, Mayo Clinic
Literatures
- PMID: 23459451
Last updated: 2012-09-12